← FDA DRUG APPROVALS

FDA ANDA · ANDA209526

CARFILZOMIB

Sponsor: MSN

APPLICATION
ANDA209526
TYPE
ANDA
ORIGINAL APPROVAL
2026-07-20
LATEST ACTION
2026-07-20
ROUTE
INJECTION, INTRAVENOUS
DOSAGE FORM
INJECTABLE, POWDER
MARKETING STATUS
None (Tentative Approval), Prescription

Products

CARFILZOMIBNone (Tentative Approval)
CARFILZOMIB 30MG · INJECTABLE · INJECTION
CARFILZOMIBNone (Tentative Approval)
CARFILZOMIB 60MG · INJECTABLE · INJECTION
CARFILZOMIBPrescription
CARFILZOMIB 60MG/VIAL · POWDER · INTRAVENOUS

Approval history

2026-07-20UNKNOWN · Original · standardAP
2026-07-20UNKNOWN · Original · standardTA
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →